OncoPharm

We review a clever study looking at neoadjvuant & adjuvant pembrolizumab vs. only adjuvant pembrolizumab in melanoma. Link: 10.1056/NEJMoa2211437 We also discuss some updates on abemaciclib and osimertinib

Landkarmks of OncoPharm: Dose-Adjusted EPOCH (+ R) This episode focuses on the pharmacodynamic rationale for the protocol and delivery, not so much the details of the literature supporting its use. Wilson et al 2002, Blood: https://doi.org/10.1182/blood.V99.8.2685

Cannabinoids appear to impact immune system function, so could cannabis use blunt the effect of immune checkpoint inhibitors? I don't know, brah. Maybe? Review: https://pubmed.ncbi.nlm.nih.gov/?term=35749680 Cannabis associated with poorer ORR: https://doi.org/10.1634/theoncologist.2018-0383 Cannabis associated with poorer TTP & OS: https://doi.org/10.3390/cancers12092447

Ide-Cel vs. "standard" treatment in relapsed/refreactory multiple myeloma study - the KarMMa-3 trial - is discussed. Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2213614

CodeBreak200: docetaxel vs. sotorasib in 2nd-line metastatic NSCLC (KRAS-G12C). A new safety signal emerges. https://doi.org/10.1016/S0140-6736(23)00221-0 A new survival prediction model for elderly patients with AML not receiving intensive therapy. https://doi.org/10.1002/cncr.34609

First - despite what you'll hear - it is pirTobrutinib, not pirobrutinib. Second - lots of great information on the current state of targeted therapies in adjuvant NSCLC and on two exciting new drugs: elacestrant and pirtobrutinib.

Tucatinib's FDA-approval (with trastuzumab) for HER2 amplified metastatic colorectal cancer launches a new era of targeted therapy in colorectal cancer. Targeting HER2 (amplified in ~3-5% of advanced colorectal cancers) in colorectal cancer will likely evolve over the coming years, so a brief history on how it has evolved so far may be helpful.

The Landmarks in OncoPharm series returns to discuss adjuvant interferon in melanoma. ECOG 1684: https://pubmed.ncbi.nlm.nih.gov/?term=36649675 Commentary on E1684: https://ascopubs.org/doi/abs/10.1200/JCO.22.02354

Explore the intricate world of breast cancer with insights on incidence, mortality, and defining risk factors like genetics and estrogen exposure. Discover the various subtypes of breast cancer, including luminal and triple-negative, and the significance of screening. Learn about surgical options, the timing of chemotherapy, and who needs it. Delve into hormonal therapies, the chronic nature of hormone-positive disease, and recent advances like CDK4/6 inhibitors and immunotherapy. A comprehensive overview packed with essential information!

New Year - New Drug, mosunetuzumab (a CD3-CD20 T-cell engager) is approved for r/r Follicular Lymphoma. And an intriguing retrospective cohort study found a higher rate of neutropenia with same-day pegfilgrastim in patients receiving dose-dense AC. Link: https://doi.org/10.1177/10781552221148116